Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Chief Financial Officer | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 638,113 |
Reported balance
After 2026-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-15 · Purchase · Acquired 100,000 · Balance 638,113 F1: The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date; F3: (continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; F4: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and F5: (continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;
F3: (continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;
F4: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and
F5: (continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date December 11, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,603 |
Ending reported balance
After 2023-12-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-12-11 · Sale · Disposed 1,410 · Balance 74,693 Row 2 · 2023-12-11 · Sale · Disposed 3,120 · Balance 71,573 Row 3 · 2023-12-11 · Sale · Disposed 7,970 · Balance 63,603 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2022 Filed Dec 30, 2022 01:48 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000141 · wf-form4_167236489532222.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This reflects the number of restricted stock units that vested on December 27, 2022. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 21:48 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 19,364 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000805928-22-000129 · wf-form4_167122726720166.xml · derivative · entry 3 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,636 Underlying: Common Stock · 19,364 shares Expires 2023-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:48 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 8,930 | $10.93 | $97,604.90 |
DisclosureSEC source: 0000805928-22-000129 · wf-form4_167122726720166.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,132 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 19,364 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 10,434 shares of common stock. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:48 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 19,364 | $5.04 | $97,594.56 |
DisclosureSEC source: 0000805928-22-000129 · wf-form4_167122726720166.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 19,364 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 10,434 shares of common stock. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:53 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 10,649 | $11.88 | $126,510.12 |
DisclosureSEC source: 0000805928-22-000123 · wf-form4_166881200162320.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,698 F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.18 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 19:51 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 947 | $8.40 | $7,954.80 |
DisclosureSEC source: 0000805928-22-000084 · wf-form4_165834665653448.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,347 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 19:51 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000084 · wf-form4_165834665653448.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,294 F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 103,079 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · derivative · entry 5 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,079 Underlying: Common Stock · 103,079 shares Expires 2032-03-16 F6 · derivative.exercise_price: The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant. F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 76,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · derivative · entry 4 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,780 Underlying: Common Stock · 76,780 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · derivative · entry 3 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,769 | $7.97 | $22,068.93 |
DisclosureSEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,584 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 950 | $8.42 | $7,999.00 |
DisclosureSEC source: 0000805928-22-000011 · wf-form4_164513213910257.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,353 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,157 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000011 · wf-form4_164513213910257.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,303 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:28 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000182 · wf-form4_164081332473376.xml · derivative · entry 3 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 Underlying: Common Stock · 5,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:28 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 648 | $9.74 | $6,311.52 |
DisclosureSEC source: 0000805928-21-000182 · wf-form4_164081332473376.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,146 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:28 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000182 · wf-form4_164081332473376.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000176 · wf-form4_164020724990588.xml · derivative · entry 3 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 757 | $9.24 | $6,994.68 |
DisclosureSEC source: 0000805928-21-000176 · wf-form4_164020724990588.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,169 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000176 · wf-form4_164020724990588.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 20:14 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 918 | $19.20 | $17,625.60 |
DisclosureSEC source: 0000805928-21-000143 · wf-form4_162689842781572.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,026 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:14 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000143 · wf-form4_162689842781572.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,944 F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 30,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000058 · wf-form4_161610439646610.xml · derivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 61,000 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000058 · wf-form4_161610439646610.xml · derivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 61,000 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 789 | $18.70 | $14,754.30 |
DisclosureSEC source: 0000805928-21-000022 · wf-form4_161368651610562.xml · nonDerivative · entry 4 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,234 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,165 | $18.71 | $40,507.15 |
DisclosureSEC source: 0000805928-21-000022 · wf-form4_161368651610562.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,866 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,157 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000022 · wf-form4_161368651610562.xml · nonDerivative · entry 3 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,023 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 7,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000022 · wf-form4_161368651610562.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,031 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:56 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,293 | $17.81 | $23,028.33 |
DisclosureSEC source: 0001179110-20-012288 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:56 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 5,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012288 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,669 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 17:54 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 481 | $16.42 | $7,898.02 |
DisclosureSEC source: 0001179110-20-012162 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,419 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 17:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012162 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Options (Right to Purchase) · Derivative | 60,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · derivative · entry 6 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 60,000 shares Expires 2023-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,745 | $12.41 | $21,662.43 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 5 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.14 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 4 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 12,854 | $12.41 | $159,518.14 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 4 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,745 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.05 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,084 | $12.41 | $13,452.44 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 3 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,599 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.05 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 60,000 | $12.41 | $744,720.00 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,683 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.06 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 60,000 | $5.04 | $302,400.00 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003914 · edgar.xml · derivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 43,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001179110-20-003914 · edgar.xml · derivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 846 | $14.68 | $12,419.28 |
DisclosureSEC source: 0001179110-20-001954 · edgar.xml · nonDerivative · entry 4 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,683 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001954 · edgar.xml · nonDerivative · entry 3 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,529 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,410 | $14.68 | $35,378.80 |
DisclosureSEC source: 0001179110-20-001954 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,372 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 7,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001954 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,782 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,049 | $16.73 | $17,549.77 |
DisclosureSEC source: 0001179110-19-013084 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,433 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013084 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,482 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,355 | $17.57 | $41,377.35 |
DisclosureSEC source: 0001179110-19-002057 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,682 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2019. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 7,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002057 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,037 F1 · shares: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:36 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014320 · edgar.xml · derivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:36 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 41,800 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001179110-18-014320 · edgar.xml · derivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,800 Underlying: Common Stock · 41,800 shares Expires 2028-12-27 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.